Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand
Doctor of Philosophy (Health Sciences), 2023
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Theses and Dissertations |
| Language: | English |
| Published: |
Prince of Songkla University
2023
|
| Subjects: | |
| Online Access: | http://kb.psu.ac.th/psukb/handle/2016/19258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Prince of Songkhla University |
| Language: | English |
| id |
th-psu.2016-19258 |
|---|---|
| record_format |
dspace |
| spelling |
th-psu.2016-192582023-12-20T09:05:02Z Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand การศึกษาต้นทุนอรรถประโยชน์ ยาภูมิคุ้มกันมะเร็งในผู้ป่วยมะเร็งปอดชนิดเซลล์ไม่เล็กที่กลับเป็นซ้ำหลังจากได้รับการรักษายาเคมีบำบัดในประเทศไทย Geater, Sarayut L. Paramee Thongsuksai Faculty of Medicine (Health Sciences) คณะแพทยศาสตร์ (วิทยาศาสตร์สุขภาพ) non-small cell lung cancer catastrophic health expenditure disparity Doctor of Philosophy (Health Sciences), 2023 Introduction: Lung cancer is the most common cancer in males and the fourth most common in females. Although there are many novel effective treatments available on the market, patients are mainly unable to access them. The biggest barrier factor is the cost of treatment which may cause financial toxicity to the patients, family, or even to the healthcare system, especially in low or middle-income countries. This study aims to (1) evaluate the cost-effectiveness of applying immune checkpoint inhibitors (ICI) in second-line non-small cell lung cancer in Thailand., and (2) evaluate the financial toxicity among lung cancer patients in Thailand. Materials and Methods: Economics evaluation using clinical input from published clinical trials data together with the cost and utility information from face-to-face questionnaire interviews. The incremental cost-effectiveness of ICI compared with docetaxel was computed using partition survival and the Markov model. Financial toxicity evaluation using data from the questionnaires in the cross-sectional design. Results: The ICI treatment improved survival by 0.55 to 0.81 life years. The incremental cost of ICI treatment ranged from USD 18,683 for atezolizumab to USD 69,723 for pembrolizumab. The ICI treatment improves QALY of about 0.43-0.62. The ICER for nivolumab, pembrolizumab, and atezolizumab were USD 84,957, USD 115,365, and USD 30,003, respectively. About 66% of the patients with lung cancer experience catastrophic health expenditure (CHE) and 29% of the patients develop medical impoverishment. Conclusion: The ICI treatment provided better survival and QALY but was more costly. Atezolizumab was the most favored regimen compared with the other two ICI. However, the ICER for atezolizumab was higher than Thailand's cost-effectiveness acceptability threshold of USD 5,208. A significant proportion of lung cancer patients in Thailand experienced financial toxicity. 2023-12-20T09:04:38Z 2023-12-20T09:04:38Z 2023 Thesis http://kb.psu.ac.th/psukb/handle/2016/19258 en Attribution-NonCommercial-NoDerivs 3.0 Thailand http://creativecommons.org/licenses/by-nc-nd/3.0/th/ application/pdf Prince of Songkla University |
| institution |
Prince of Songkhla University |
| building |
Khunying Long Athakravi Sunthorn Learning Resources Center |
| continent |
Asia |
| country |
Thailand Thailand |
| content_provider |
Khunying Long Athakravi Sunthorn Learning Resources Center |
| collection |
PSU Knowledge Bank |
| language |
English |
| topic |
non-small cell lung cancer catastrophic health expenditure disparity |
| spellingShingle |
non-small cell lung cancer catastrophic health expenditure disparity Geater, Sarayut L. Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| description |
Doctor of Philosophy (Health Sciences), 2023 |
| author2 |
Paramee Thongsuksai |
| author_facet |
Paramee Thongsuksai Geater, Sarayut L. |
| format |
Theses and Dissertations |
| author |
Geater, Sarayut L. |
| author_sort |
Geater, Sarayut L. |
| title |
Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| title_short |
Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| title_full |
Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| title_fullStr |
Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| title_full_unstemmed |
Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand |
| title_sort |
cost-utility analysis of immuno-oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in thailand |
| publisher |
Prince of Songkla University |
| publishDate |
2023 |
| url |
http://kb.psu.ac.th/psukb/handle/2016/19258 |
| _version_ |
1787137887418974208 |